Primary record
4-PIPERIDINEMETHANOL, .ALPHA.-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-, (.ALPHA.R)-
- 库存
- 5,345 克
- 纯度
- 98.8 %
- CAS
- 139290-65-6
化合物标识与属性
- CAS
- 139290-65-6
- PubChem CID
- 5311271
- SMILES
- COC1=CC=CC(=C1OC)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O
- Canonical SMILES
- COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC
名称与同义词
- Volinanserin
- Volinanserina
- Volinanserine
- 139290-65-6
- volinanserinum
- Mdl 100907
- Volinanserin [INN]
- MDL-100907
- AC1NSKC8
- RefChem:902049
- EW71EE171J
- UNII-EW71EE171J
- DTXSID6047363
- Mdl 100,907
- MFCD00909060
- CHEMBL74355
- D0HZ2E
- D0S6PV
- M100907
- Volinanserin Hydrochloride Salt
- C22H28FNO3
- MDL100.907
- MDL100907
- DTXCID4027363
- GTPL185
- MDL-100,907
- SCHEMBL675164
- MDL-100907(Volinanserin)
- orb1301831
- SCHEMBL29356737
- MDL-100.907
- HXTGXYRHXAGCFP-OAQYLSRUSA-N
- MDL100105
- Serotonin 5-HT2 Receptor Antagonists
- ZINC598040
- EX-A3509
- KS-000007QR
- C22-H28-F-N-O3
- Tox21_300244
- BDBM50095027
- HB1780
- M-100907
- AKOS022180892
- CID5311271
- FV28720
- MDL 100105
- MDL-100970
- CID:5311271
- NCGC00247964-01
- NCGC00254173-01
- (R)-(2,3-Dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol
- AC-36402
- AJ-23647
- AS-35103
- DA-59040
- HY-14940
- SID:99381484
- J555.944H
- CAS-139290-65-6
- CS-0003646
- (R)-(+)-MDL 100907
- (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol
- Q-3721
- M100907, >=98% (HPLC)
- A886060
- C079049
- alpha-(2,3-Dimethoxyphenyl)-1-(2-(4-fluorophenylethyl))-4-piperidine methanol
- M 100907
- Q7940202
- BRD-K23647661-001-02-2
- (R)-(2,3-dimethoxyphenyl)(1-(2-(4-fluorophenyl)ethyl)piperidin-4-yl)methanol
- - -ALPHA- -1-[2- ETHYL]-4-PIPERIDINEMETHANOL
- 4-Piperidinemethanol, alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-, (alphaR)-
- (+)-alpha-(2,3-Dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol
- (R)-(2,3-Dimethoxy-phenyl)-{1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-methanol
- 4-piperidinemethanol, alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (alpha-R)-
- (R)-(1-(4-fluorophenethyl)piperidin-4-yl)(2,3-dimethoxyphenyl)methanol
- (2,3-Dimethoxy-phenyl)-{1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-methanol
- (a-R)-a-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
- (alphaR)-alpha-(2,3-Dimethoxyphenyl)-1-(4-fluorophenethyl)-4-piperidinemethanol
- (alphaR)-alpha-[1-(4-Fluorophenethyl)-4-piperidinyl]-2,3-dimethoxybenzyl alcohol
- (R)-(+)-?-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperinemethanol
- (R)-(+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol
- (R)-(2,3-dimethoxyphenyl)({1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl})methanol
- (R)-(2,3-dimethoxyphenyl)-(1-(2-(4-fluorophenyl)ethyl)piperidin-4-yl)methanol
- (R)-(2,3-Dimethoxyphenyl)-(1-(2-p-fluorophenylethyl)-piperidine-4-yl)-methanol
- (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]-4-piperidyl]methanol
- (R)-(2,3-Dimethoxyphenyl){1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}methanol
- (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
- (R)-alpha-[1-[2-(4-Fluorophenyl)ethyl]piperidine-4-yl]-2,3-dimethoxybenzyl alcohol
- (R)-alpha-[1-[2-(4-Fluorophenyl)ethyl]piperidine-4-yl]-alpha-(2,3-dimethoxyphenyl)methanol
- 4-Piperidinemethanol, |A-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-, (|AR)-
- 4-PIPERIDINEMETHANOL, A-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-, (AR)-
- 4-Piperidinemethanol, alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (+)-
- (2,3-Dimethoxy-phenyl)-{1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-methanol (M 100907)
- (2,3-Dimethoxy-phenyl)-{1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-methanol(MDL 100907)
- (R)-(+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUORO-PHENYL)ETHYL]-4-PIPERIDINE METHANOL
- 4-PIPERIDINEMETHANOL, .ALPHA.-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-, (.ALPHA.R)-
- 4-PIPERIDINEMETHANOL, ALPHA-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-, (R)-
- 604-124-1